Frequently Asked Questions
The global sicca syndrome (Sjogren) market is projected to grow at a CAGR of 14% during the forecast period of 2022-2029.
Factors such as increasing awareness of healthcare infrastructure and increase in diagnostic tests are acting as the major drivers for the global sicca syndrome (Sjogren) market.
The major players operating in the Sicca Syndrome (Sjogren) Market are GlaxoSmithKline plc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Eli Lily and Company (U.S.), Pfizer Inc. (U.S.), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), Boehringer Ingelheim International Gmbh (Germany), Sanofi (France), Astrazeneca (U.K.), AbbVie Inc. (U.S.), Abbott (U.S.), Bayer AG (Germany), Johnson & Johnson Services, Inc. (U.S.).
The major countries covered in the Sicca Syndrome (Sjogren) Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
